Latest News



Ario Pharma Commences Efficacy Trial of TRPV1 Inhibitor in Chronic Idiopathic Cough.

Cambridge, UK, 09 July 2014: Ario Pharma Ltd, the biopharmaceutical company developing innovative new treatments for respiratory disease, announced today that it has commenced a Phase IIa study of its oral TRPV1 antagonist, XEN-D0501, for the treatment and prevention of cough in patients with chronic idiopathic cough (CIC). Approximately 20 patients will be enrolled into the...


Apica Cardiovascular sold to Thoratec for $75m.

3rd July 2014, Dublin Ireland. Seroba Kernel Life Sciences, a European life science venture capital company based in Dublin, is pleased to announce the sale of its investee company, Apica Cardiovascular, to Thoratec Corporation (NASDAQ: THOR) for $75m. Apica has developed an innovative transapical access and closure system that can simplify and standardize the technique used...


< back to home page